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AbstrACt
Introduction Azithromycin has been given for tropical 
infectious diseases such as trachoma and yaws by mass 
drug administration (MDA). As well as controlling the 
infectious disease in question, MDA may have a beneficial 
effect in reducing mortality in young children. However, the 
dose, formulation, frequency and duration of azithromycin 
used in certain infectious diseases may vary in different 
studies, and these differences may have impacts on 
the effectiveness of azithromycin MDA. Furthermore, 
whether the dose, formulation, frequency and duration 
are associated with the effectiveness of azithromycin 
for reducing child mortality—if indeed this effect can 
be confirmed—remain unknown. In this study, we will 
investigate whether different strategies such as different 
dose, formulation, frequency and duration affect the 
effectiveness of azithromycin MDA on the prevalence of 
certain infectious diseases or child mortality.
Methods and analysis A narrative systematic review 
will be conducted according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
statement. PubMed, Embase, the Cochrane Central 
Register of Controlled Trials, Web of Science,  ClinicalTrials. 
gov and WHO International Clinical Trials Registry Platform 
will be searched. No language restrictions will be applied. 
All randomised/quasi-controlled trials, observational 
studies (cross-sectional studies, cohort studies and 
case–control studies), case series and registered protocols 
will be considered. Dose, duration, frequency, rounds and 
formulations of azithromycin used in MDA will be collected 
and reviewed. The outcomes will be disease prevalence/
control in children and child mortality. Data from the 
individual studies will not be pooled.
Ethics and dissemination Formal ethical approval is 
not required since data will be collected from published 
studies. This systematic review will be published in a peer-
reviewed journal and presented at conference meetings.
PrOsPErO registration number CRD42018114902
IntrOduCtIOn
Mass drug administration (MDA), a key 
strategy for controlling infectious diseases, 
aims to give whole populations a pharmaceu-
tical agent to reduce or interrupt pathogen 
transmission.1 In low-income and middle-in-
come countries, MDA has been widely used 
in several diseases, including: trachoma, yaws, 
onchocerciasis, lymphatic filariasis, schisto-
somiasis and infection with soil-transmitted 
helminths.2 Azithromycin, one of the MDA 
drugs, is a macrolide antibiotic with a long 
half-life and low toxicity. It has a wide-spec-
trum bacteriostatic property against both 
gram-positive, gram-negative bacteria, atypical 
bacteria and some protozoa. Azithromycin is 
well tolerated and appears to be safe for use 
in children and pregnant women.3 4 Thus, 
azithromycin is generally accepted in MDA 
practice, including the control of trachoma 
and yaws especially in children5 6(summarised 
in table 1).
MDA with azithromycin was first used for 
trachoma control.5 WHO recommendations 
for trachoma are for MDA when the preva-
lence of trachomatous inflammation-follic-
ular in children aged 1–9 years is ≥5% (with 
differing number of rounds depending on 
prevalence categories 5%–9.9%, 10%–19.9%, 
20%–29.95% and ≥30%)7 (table 1). It has also 
been shown to be beneficial for the control of 
yaws.6 WHO’s strategy for eradication of yaws 
What is already known on this topic?
 ► Mass drug administration (MDA) is a key strategy for 
controlling a few infectious diseases.
 ► WHO recommends azithromycin as an effective 
agent used in MDA for controlling several infectious 
diseases.
 ► MDA may reduce child mortality in young children.
What this study hopes to add?
 ► The most effective dose, formulation, frequency and 
duration of azithromycin to facilitate the effects of 
MDA.
 ► Whether dose, formulation, frequency and duration 
of azithromycin make a difference to the possible 
effect of azithromycin MDA on child mortality.
 ► Whether age affects the effectiveness of azithromy-
cin MDA.
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Table 1 WHO strategies for azithromycin mass drug administration (MDA) in children
Diseases
Purpose of 
MDA Location
WHO 
recommended 
dose
WHO 
recommended 
frequency
WHO recommended 
duration
Combination 
intervention
Trachoma Control Districts with 
TF
1-9
*≥5%
20 mg/kg up to 
1 g
Annually At least three doses (years) 
where TF
1-9
*≥10%
SAFE†
Yaws Eradication Yaws-endemic 
areas
30 mg/kg up to 
2 g
Annually One single dose None
*TF in children aged 1–9 years.
†Surgery for trichiasis, antibiotic treatment, facial cleanliness and environmental improvement.
TF, trachomatous inflammation-follicular.
recommends a single round of 30 mg/kg azithromycin 
MDA with coverage of >90% followed by targeted treat-
ment programmes8 (table 1). Furthermore, it may have 
potential beneficial effects for malaria control, because 
of reduced prevalence after MDA administration.9 In 
addition, a few studies also found that azithromycin 
MDA may play a role in deceasing childhood mortality 
by reducing the rate of respiratory infections, diarrhoea 
and malaria.10–12
Azithromycin MDA has been exerting benefits on 
decreasing the prevalence of some infectious diseases 
like trachoma and yaws. The goal of elimination of 
trachoma as a public health problem or eradication of 
yaws has been achieved in some places. However, these 
diseases still persist in some districts.13 14 The dose, 
formulation, frequency and duration of azithromycin 
used in certain infectious diseases may vary in different 
studies. For example, a 30 mg/kg dose was used in 
studies of azithromycin’s efficacy against yaws,6 15 while 
other studies investigated the effectiveness of 20 mg/
kg.16–18 For trachoma control, two types of formulation 
including suspension and tables were reported. The 
frequency of azithromycin MDA has also varied: annu-
ally, biannually as well as quarterly administration were 
adopted among different studies.19 20 Furthermore, the 
duration of administration has ranged from 1 to 7 years 
based on different baseline prevalence.21 22 In this system-
atic review, we aim to summarise the variations in dose, 
formulations, frequency and duration of azithromycin, 
and explore whether the effectiveness of azithromycin in 
reducing the prevalence of certain infectious diseases in 
children and child mortality is influenced by any of these 
factors. Additionally, we will explore the possible differ-
ence of azithromycin MDA in different age groups.
rEvIEW quEstIOns
1. To summarise the existing evidence on dose, formula-
tion, frequency and duration of azithromycin for MDA 
in children with infectious diseases.
2. To investigate whether the dose, formulation, frequen-
cy or duration affects the success of MDA in children—
both in terms of prevalence in certain infectious dis-
eases and overall child mortality.
3. To explore the different effectiveness in different age 
groups receiving MDA.
sEArChEs
PubMed, Embase, the Cochrane Central Register of 
Controlled Trials, Web of Science,  ClinicalTrials. gov and 
WHO International Clinical Trials Registry Platform will 
be searched. A searching strategy has been developed 
(online supplementary appendix 1) and the searching 
process will be updated before submission. The refer-
ence lists of selected articles will be checked for addi-
tional studies. No language restrictions will be applied.
To identify studies regarding azithromycin, the keywords 
‘azithromycin’ or ‘sumamed’ or ‘zithromax’ will be used. 
For MDA research, the keywords ‘mass drug adminis-
tration’ or ‘mass administration’ or ‘mass treatment’ or 
‘mass distribution’ or ‘preventative chemotherapy’ or 
‘MDA’ will be used to select the studies involving MDA. 
Then, the above two steps will be combined.
tyPEs Of study tO bE InCludEd
Population
Children aged up to 15 years old.
Intervention
Azithromycin MDA and the dose, formulation, frequency 
and duration of administration for whole population 
(data for children subgroup can be obtained) or chil-
dren.
Comparison
For randomised/quasi-controlled trials: comparisons are 
placebo, or no treatment, or other medicine, or different 
dose, formulation, frequency and duration of azithro-
mycin MDA.
For observational studies, case series and published 
protocols: no comparison.
Outcome
1. Summarise the doses, formulation, frequency and du-
ration of azithromycin MDA used for each infectious 
disease.
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2. Effect on prevalence of infectious disease in children, 
for which the azithromycin MDA was distributed by 
dose, duration and frequency, with subgroup analysis 
by age group.
3. Effect on child mortality by dose, duration and fre-
quency, with subgroup analysis by age group.
study design
Study inclusion and exclusion criteria
Inclusion criteria: (1) Randomised/quasi-controlled 
trials, observational studies (cross-sectional studies, 
cohort studies and case–control studies), case series or 
published protocols that have investigated azithromycin 
MDA, (2) Children are included and (3) Disease prev-
alence/control, child mortality after azithromycin MDA 
were reported.
Exclusion criteria: (1) Mathematical modelling studies, 
animal studies, case reports, editorials, conference 
abstracts and reviews and (2) Independent outcome for 
children not listed
sElECtIOn Of studIEs
After removal of duplications, titles and abstracts will 
initially be screened for relevance. Full texts of poten-
tially relevant studies that passed the initial screening will 
be reviewed for eligibility. Two review authors (YY and 
TX) will assess the trials for eligibility and methodolog-
ical quality without consideration of the results. Any disa-
greement will be discussed until we reached consensus. 
If unresolved, a third reviewer (LZ) will be involved. 
Reasons for excluding any trial will be documented.
dAtA ExtrACtIOn And MAnAgEMEnt
The candidate articles will be imported to EndNote. 
Standardised forms in Excel will be used. Two review 
authors (YY and TX) will extract the data and check for 
discrepancies at each level (title, abstract and full paper) 
using the inclusion and exclusion criteria. We will extract 
data regarding:
1. General information: the infectious disease that MDA 
was given for, author, year(s) the study took place, year 
of publication, country, sample size, sociodemograph-
ics of participants and setting.
2. Study methodology: study design, included/excluded 
criteria for participants and guideline source.
3. Details of azithromycin MDA: dose, formulation, fre-
quency, duration and combination with other medi-
cines;
4. Comparison: details for placebo or no treatment, or 
other medicine.
5. Possible social and financial factors contributing to 
MDA administration: such as gender.
6. Study outcomes and limitations.
7. Discussion re possible factors for effectiveness of azith-
romycin MDA.
rIsk Of bIAs (quAlIty) AssEssMEnt
Two reviewers (YY and TX) will independently assess the 
risk of bias of included studies. We will rate the quality 
of the evidence using Oxford Centre for Evidence-based 
Medicine's Levels of Evidence and Grades of Recommen-
dation. For randomised studies, we will use the criteria 
outlined in the Cochrane Handbook for Systematic 
Reviews of interventions.23 Risk of bias will be assessed 
according to the following criteria:
 ► Random sequence generation (selection bias).
 ► Allocation concealment (selection bias).
 ► Blinding of participant and personnel (performance 
bias).
 ► Blinding of outcome assessment (detection bias).
 ► Incomplete outcome data (attrition bias).
 ► Selective reporting and whether the study was free of 
selective outcome reporting (reporting bias).
For non-randomised studies, the modified the risk 
of bias in non-randomized studies of interventions 
(ROBINS-I) tool will be used for the assessment of the 
quality in terms of seven domains.24 25
strAtEgy fOr dAtA synthEsIs
We will not pool the data from the individual studies. A 
narrative systematic review will be conducted according 
to Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses statement26 http://www. prisma- statement. 
org. A flow diagram will summarise the number of arti-
cles retained at each screening stage and provide the 
reasons for exclusion. Extracted data from all studies will 
be narratively presented through tables.
AnAlysIs Of subgrOuPs Or subsEts
Subgroups will be defined by (1) type of diseases, such 
as trachoma, yaws, malaria, and doses, formulations, 
frequencies and durations in each disease will be assessed 
and (2) paediatric patients in different age groups.
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